ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme
Trial details
- Registry ID
- NCT04587830
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma MultiformeNCT04587830 | Polaris Group | Phase 2 | Active not recruiting | 2027-02-28Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |